Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche EGRF Outlook: Iressa Review Gives “Encouragement” To Tarceva 

Executive Summary

Roche's outlook for Tarceva in non-small cell lung cancer received a "margin of encouragement" from the Iressa FDA advisory committee review, Pharmaceuticals Head William Burns said on a conference call Oct. 10

You may also be interested in...



OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates

OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil

OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates

OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil

Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI

Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said

UsernamePublicRestriction

Register

PS040630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel